Edwards Lifesciences (EW) Total Liabilities (2009 - 2026)

Edwards Lifesciences' Total Liabilities history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 5.76% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 5.76% increase from a year earlier, with the FY2025 full-year figure at $3.4 billion, up 12.27% from the prior year.
• Total Liabilities retreated to $3.0 billion in Q1 2026 per EW's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $3.4 billion in Q3 2024 and bottomed at $2.4 billion in Q3 2022.
• The 5-year median for Total Liabilities is $2.6 billion (2023), against an average of $2.8 billion.
• Across the five-year window, Total Liabilities tumbled 67.61% in 2022 and climbed 27.09% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $2.5 billion in 2022, then rose by 6.36% to $2.6 billion in 2023, then rose by 13.19% to $3.0 billion in 2024, then gained by 12.27% to $3.4 billion in 2025, then fell by 10.89% to $3.0 billion in 2026.
• Per Business Quant, the three latest EW Total Liabilities figures stand at $3.0 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.1 billion (Q3 2025).